Why eFFECTOR Therapeutics Shares Trading Higher Today
Portfolio Pulse from Vandana Singh
eFFECTOR Therapeutics announced interim data updates from a Phase 2 expansion cohort evaluating zotatifin combined with fulvestrant and abemaciclib in patients with ER+ metastatic breast cancer. The disease control rate is 74%, and the treatment was generally well tolerated. EFTR shares are up 72.7% at $0.91 during the premarket session.
May 26, 2023 | 12:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
eFFECTOR Therapeutics shares are trading higher after the company announced positive interim data from a Phase 2 trial evaluating zotatifin in ER+ metastatic breast cancer patients.
The positive interim data from the Phase 2 trial indicates that the treatment is effective and well tolerated, which is likely to boost investor confidence in the company's product pipeline and potential for future revenue growth. This news directly impacts EFTR's stock price, as evidenced by the 72.7% increase in premarket trading.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100